Isotope Effects in Complex Scattering Lengths for He Collisions With Molecular Hydrogen

We examine the effect of theoretically varying the collision-system reduced mass in collisions of He with vibrationally excited molecular hydrogen and observe zero-energy resonances for select atomic “hydrogen” masses less than 1 u or a “helium” mass of 1.95 u. Complex scattering lengths, state-to-state vibrational quenching cross sections, and a low-energy elastic scattering resonance are all studied as a function of collision-system reduced mass. Experimental observations of these phenomena in the cold and ultracold regimes for collisions of $^{3}$He and $^{4}$He with H$_{2}$, HD, HT, and DT should be feasible in the near future.Astronom

Observations of a Two-Stage Solar Eruptive Event (SEE): Evidence for Secondary Heating

We present RHESSI, SDO/AIA, SOHO/LASCO, STEREO, and GOES observations of a partially occulted solar eruptive event (SEE) that occurred at the South-West limb on 8 March, 2011. The GOES X-ray light curve shows two peaks separated by almost two hours that we interpret as two stages of a single event associated with the delayed eruption of a CME. A hot flux rope formed during the first stage and continued expanding and rising throughout the event. The speed of the flux rope decreased from approx.120 to 14 km/s during the decay phase of the first stage and increased again during the second stage to become the CME with a speed of approx.516 km/s. RHESSI and GOES data analyses show that the plasma temperature reached over 20 MK in the first stage, then decreased to approx.10 MK and increased to 15 MK in the second stage. This event provides clear evidence for a secondary heating phase. The enhanced EUV and X-ray emission came from the high corona ( approx.60 arcsec above the limb) in the second stage, approx.40 arcsec higher than the site of the initial flare emission. STEREO-A on-disk observations indicate that the post-flare loops during this stage were of larger scale sizes and spatially distinct from those in the first stage

Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy

<p>Abstract</p> <p>Background</p> <p>Cardiovascular magnetic resonance (CMR) can provide quantitative data of the myocardial tissue utilizing high spatial and temporal resolution along with exquisite tissue contrast. Previous studies have correlated myocardial scar tissue with the occurrence of ventricular arrhythmia. This study was conducted to evaluate whether characterization of myocardial infarction by CMR can predict cardiovascular events in patients with ischemic cardiomyopathy (ICM).</p> <p>Results</p> <p>We consecutively studied 86 patients with ICM (LVEF < 50%, mean LVEF: 26 ± 12%) with CMR before revascularization or medication therapy ± implantable cardiac defibrillator, determined the amount of myocardial scar, and followed for development of cardiovascular events. Thirty-three patients (38%) had cardiovascular events (mean follow-up: 20 ± 16 months). Patients who developed cardiovascular events had larger scar volume and scar percentage of the myocardium than those who did not develop cardiovascular events (16.8 ± 12.4 cm3 vs. 11.7 ± 12.6 cm3, p = 0.023 and 10.2 ± 6.9% vs. 7.2 ± 6.7%, p = 0.037, respectively). There were no significant differences in LVEDV, LVESV and LVEF between the patients with and without cardiovascular events (231 ± 76 ml vs. 230 ± 88 ml; 180 ± 73 ml vs. 175 ± 90 ml; and 25 ± 10% vs. 27 ± 13%, respectively).</p> <p>Conclusion</p> <p>Quantification of the scar volume and scar percentage by CMR is superior to LVEDV, LVESV, and LVEF in prognosticating the future likelihood of the development of cardiovascular events in patients with ICM.</p

Form of Supplemental Selenium in Vitamin-Mineral Premixes Differentially Affects Early Luteal and Gestational Concentrations of Progesterone, and Postpartum Concentrations of Prolactin in Beef Cows

Soils with marginal to deficient levels of selenium (Se) are widespread in the northwest, northeast, and southeast US. Supplementation to the diet of forage-grazing beef cattle with a vitamin-mineral mix containing additional Se is recommended in these geographic regions. We have reported that the form of supplemental Se provided to Angus-cross beef cows can affect circulating levels of progesterone (P4) on day 6 of the estrous cycle, a time when increased P4 is known to promote fertility. The objectives of this study were to (1) confirm and expand upon our initial report that the form of Se provided to cows affects early luteal-phase concentrations of systemic P4, (2) determine the effects of the form of Se on concentrations of P4 during gestation, and (3) determine the effects of the form of Se on concentrations of prolactin (PRL) during lactation. Throughout this study, Angus-cross beef cows had ad libitum access to a vitamin-mineral mix containing 35 ppm of Se in either an inorganic form (ISe) or a 1:1 mix of inorganic and organic forms (MIX). We observed a MIX-induced increase (p = 0.006) in systemic concentrations of P4 on day 7 but not on days 4 or 10 of the estrous cycle, consistent with our earlier report. We observed a MIX-induced increase (p = 0.02) in the systemic concentration of P4 at months 1, 3, 5, and 7 of gestation, and a MIX-induced decrease (p \u3c 0.05) in systemic concentrations of PRL at months 5 and 6 of lactation. In summary, the form of Se provided to cows can be manipulated to affect the early luteal phase and gestational concentrations of P4, and postpartum concentrations of PRL

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy.

Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P &lt; 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve &gt;0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers